Lowest Price Guaranteed
Pages
188
Last Updated
October 2025
View Count
14430
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the market for NASH drugs is headed in the mid to long term.
Chapter 3 provides a general introduction to NASH, underlying the basic concepts of this disease area. In this section, we have briefly discussed the causes, classification, symptoms and different stages of NASH. Additionally, we have highlighted the historical evolution, pathogenesis, prevalence and the target patient population of NASH.
Chapter 4 gives an overview of the treatment and diagnostic solutions associated with NASH. We have discussed, in detail, the general recommendations, pharmacological interventions and natural remedies for treatment of the disease. This chapter also covers the non-invasive means of evaluating and staging NAFLD patients.
Chapter 5 summarises the market dynamics of NASH. It highlights the key drivers and restraints likely to influence the evolution of this market. In addition, it also covers the various research and development initiatives which have been takenby different stakeholders in this domain.
Chapter 6 provides a comprehensive market overview highlighting the therapeutics being developed to treat NASH. It offers an elaborate analysis of the drugs under development with their phase of development, route of administration, type of molecule and the mechanism of action.
Chapter 7 presents detailed profiles of the drugs in advanced stages of development.Each profile provides the drug overview, background, mechanism of action, current development status, key clinical trials, respective results andother recent developments associated with the drug.
Chapter 8 offersa scenario based approach to determine the overall market opportunity for NASH drug developers in the coming decade. The analysis highlights the likely evolution of important parameters such as the diagnosis rate, drug penetration rates and annual pricing. In addition, we have also presented an indicative distribution of the overall market amongst the different drugs likely to be launched in the near future..
Chapter 9 provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, product portfolio, recent collaborations and future outlook.
Chapter 10 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapter 11 is a collection of interview transcripts of the discussions which were held during the course of this study. For the purposes of this study, we held discussions with seniormost representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.
Chapter 12 is an appendix which provides tabulated data and numbers for all the figures provided in the report.
Chapter 13 is an appendix which provides the list of companies mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. The Concept of NASH
3.3. Target Patient Population
3.4. Pathogenesis of NASH
3.5. Epidemiology
3.6. Animal Models for NASH
3.7. Clinical Trial Designs and End Points
3.8. Regulatory Initiatives
4. TREATMENT OPTIONS AND DIAGNOSTIC SOLUTIONS
4.1. Context and Background
4.2. Treatment Options for NASH
4.2.1. General Recommendations
4.2.2. Pharmacological Interventions
4.2.3. Natural Products for the Treatment of NASH
4.3. Diagnostic Solutions
5. MARKET DYNAMICS
5.1. Chapter Overview
5.2. Key Growth Drivers
5.2.1. Growing Worldwide Prevalence of Obesity and Diabetes
5.2.2. Increase in Research and Development Initiatives
5.2.3. Promising Late Stage Molecules
5.3. Challenges
5.3.1. Lack of Understanding of Pathophysiology of NASH
5.3.2. Incompetent Diagnostic Tools for NASH
6. MARKET OVERVIEW
6.1. Context and Background
6.2. Pipeline of Drugs
6.3. Pipeline Analysis
6.3.1. Distribution by Phase of Development
6.3.2. Distribution by Type of Molecule
6.3.3. Distribution by Route of Administration
7. UPCOMING NASH DRUGS: DETAILED PROFILES
7.1. Context and Background
7.2. Lipaglyn, Saroglitazar (ZYH1), Zydus-Cadila
7.2.1. Drug Overview
7.2.2. Background
7.2.3. Mechanism of Action
7.2.4. Development Status
7.2.5. Key Clinical Trial Results
7.2.6. Patent Portfolio
7.3. INT-747 (Obeticholic acid (OCA))/ DSP-1747, Intercept Pharmaceuticals
7.3.1. Drug Overview
7.3.2. Background
7.3.3. Mechanism of Action
7.3.4. Development Status
7.3.5. Key Clinical Trial Results
7.3.6. Manufacturing
7.3.7. Patent Portfolio
7.3.8. Collaborations
7.4. Emricasan (IDN-6556), Conatus Pharmaceuticals
7.4.1. Drug Overview
7.4.2. Mechanism of Action
7.4.3. Development Status
7.4.4. Key Clinical Trial Results
7.4.5. Manufacturing
7.4.6. Collaborations
7.5. GFT505, Genfit
7.5.1. Drug Overview
7.5.2. Background
7.5.3. Mechanism of Action
7.5.4. Development Status
7.5.5. Key Clinical Trial Results
7.5.6. Patent Portfolio
7.5.7. Collaborations
7.6. Cenicriviroc (CVC), Tobira Therapeutics
7.6.1. Drug Overview
7.6.2. Background
7.6.3. Mechanism of Action
7.6.4. Development Status
7.6.5. Key Clinical Trial Results
7.6.6. Manufacturing
7.6.7. Collaborations
7.7. Aramchol, Galmed Pharmaceuticals
7.7.1. Drug Overview
7.7.2. Background
7.7.3. Mechanism of Action
7.7.4. Development Status
7.7.5. Key Clinical Trial Results
7.7.6. Manufacturing
7.7.7. Collaborations
7.8. Simtuzumab (GS-6624), Gilead Sciences
7.8.1. Drug Overview
7.8.2. Mechanism of Action
7.8.3. Development Status
7.8.4. Key Clinical Trial Results
7.8.5. Manufacturing
7.8.6. Patent Portfolio
7.8.7. Collaborations
7.9. Procysbi (RP103), Raptor Pharmaceuticals
7.9.1. Drug Overview
7.9.2. Background
7.9.3. Mechanism of Action
7.9.4. Development Status
7.9.5. Key Clinical Trial Results
7.9.6. Manufacturing
7.9.7. Patent Portfolio
7.9.8. Collaborations
7.10. Remogliflozinetabonate (Remo), Islet Sciences / BHV Pharma
7.10.1. Drug Overview
7.10.2. Background
7.10.3. Mechanism of Action
7.10.4. Development Status
7.10.5. Key Clinical Trial Results
7.10.6. Patent Portfolio
7.10.7. Collaborations
8. MARKET SIZING AND OPPORTUNITY ANALYSIS
8.1. Chapter Overview
8.2. Important Parameters and Key Assumptions
8.2.1. Target Patient Population
8.2.2. Diagnosis Rate
8.2.3. Drug Penetration Rate
8.2.4. Price of the Drug
8.3. Scenario Analysis: Description and Methodology
8.4. Overall NASH Market, 2015-2025
9. COMPANY PROFILES
9.1. Chapter Overview
9.2. Conatus Pharmaceuticals
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. NASH Drugs Portfolio
9.2.4. Partnerships
9.2.5. Future Outlook
9.3. Galmed Pharmaceuticals
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. NASH Drugs Portfolio
9.3.4. Partnerships
9.3.5. Future Outlook
9.5. Genfit
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. NASH Drugs Portfolio
9.5.4. Partnerships
9.5.5. Future Outlook
9.6. Gilead Sciences
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. NASH Drugs Portfolio
9.6.4. Partnerships
9.6.5. Future Outlook
9.7. Intercept Pharmaceuticals
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. NASH Drugs Portfolio
9.7.4. Partnerships
9.7.5. Future Outlook
9.8. Novo Nordisk
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. NASH Drugs Portfolio
9.8.4. Future Outlook
9.9. Raptor Pharmaceuticals
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. NASH Drugs Portfolio
9.9.4. Partnerships
9.9.5. Future Outlook
9.10. Zydus Cadila
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. NASH Drugs Portfolio
10. CONCLUSION
10.1. NASH: Emerging As the Next Epidemic
10.2. Lifestyle Interventions: A Solution To Reduce Severity of the Disease
10.3. Diagnosis of Nash Remains a Challenge
10.4. With a High Unmet Need; Nash is Anticipated To Be a Multi-Billion Market
11. INTERVIEW TRANSCRIPTS
11.1. Chapter Overview
11.2. BiOrion Technologies (Herman Steen, CEO)
11.3. Phenex Pharmaceuticals (Dr. Claus Kremoser, CEO)
11.4. Tobira Therapeutics (Laurent Fischer, CEO and Andrew McKibben, Director, Finance & Corporate Development)
11.5. Verlyx Pharma (Dr. Pierre Falardeau, CEO)
11.6. Connexios (ShobhaVijayaraghavan, VP Business Development)
12. APPENDIX1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Spectrum of Non Alcoholic Fatty Liver Disease
Figure 3.2 NAFLD: Classification
Figure 3.3 Chronology of the Pace of Research and Development for NASH
Figure 3.4 NAFLD and NASH: Pathogenesis
Figure 3.5 Prevalence of NASH
Figure 3.6 Prevalence of NASH in the US
Figure 3.7 Design and End-points for Clinical Trials of NASH
Figure 5.1 NASH Drugs Market: Key Market Drivers and Restraints
Figure 5.2 Rise in Overweight and Obesity Rate, 1980-2013
Figure 5.3 Diabetes: Worldwide Prevalence and Diagnosis (Million)
Figure 5.4 Diabetes: Prevalence by Regions /Countries (2014), Million
Figure 5.5 Diabetes: Diagnosed Cases by Regions /Countries (2014), Million
Figure 6.1 NASH Drugs: Distribution by Phase of Development
Figure 6.2 NASH Drugs: Distribution by Type of Molecule
Figure 6.3 NASH Drugs: Distribution by Route of Administration
Figure 7.1 Lipaglyn (Saroglitazar): Development Timeline
Figure 7.2 INT-747: Mechanism of Action
Figure 7.3 INT-747: Design of Phase III REGENERATE Trial
Figure 7.4 GFT505: Mechanism of Action
Figure 8.1 NASH Future Market Scenarios
Figure 8.2 Overall NASH Drugs Market, 2018- 2025 (USD Million)
Figure 8.3 NASH Drugs Market: Distribution by Region, 2025 (USD Million)
Figure 8.4 Timeline: Launch of NASH Molecules
Figure 8.5 NASH Drugs Market: Indicative Distribution by Drugs: 2020, 2025
Figure 8.6 Market Scenarios, Comparative Positioning (USD Billion)
Figure 9.1 Conatus Pharmaceuticals: NASH Drugs Pipeline
Figure 9.2 Galmed Pharmaceuticals: NASH Drugs Pipeline
Figure 9.3 Genfit: Development History
Figure 9.4 Genfit: Revenues, 2010-2014 (EUR Million)
Figure 9.5 Genfit: Distribution of Revenues, 2014 (EUR Million)
Figure 9.6 Genfit: NASH Drugs Pipeline
Figure 9.7 Gilead Sciences: Net Revenues, 2010 – H1 2015 (USD Billion)
Figure 9.8 Gilead Sciences: Distribution of Revenues, 2014 (USD Million)
Figure 9.9 Gilead Sciences: NASH Drugs Pipeline
Figure 9.10 Intercept Pharmaceuticals: Revenues, 2011- H1 2015 (USD Million)
Figure 9.11 Intercept Pharmaceuticals: NASH Drugs Pipeline
Figure 9.12 Novo Nordisk Revenues, 2010 - H1 2015 (DKK Million)
Figure 9.13 Novo Nordisk Revenues: Distribution by Business Segment, 2014 (DKK Billion)
Figure 9.14 Novo Nordisk: NASH Drugs Pipeline
Figure 9.15 Raptor Pharmaceuticals: Revenues, 2013- H1 2015 (USD Million)
Figure 9.16 Raptor Pharmaceuticals: NASH Drugs Pipeline
Figure 9.17 Zydus Cadila: Revenues, 2010-2014 (INR Billion)
Figure 9.18 Zydus Cadila: Revenues by Geographies, 2014 (INR Billion)
Figure 9.19 Zydus Cadila: NASH Drugs Pipeline
Figure 10.1 NASH Drugs Market (USD Million), 2018, 2020 and 2025
Table 3.1 Various Animal Models for the Study of NASH
Table 3.2 Important Definitions and Specifications for NASH Clinical Studies
Table 3.3 Pre-fibrotic NAFLD/ NASH: Diagnostic Categories and Associated Histologic Lesions
Table 4.1 Recommended Nutritional Guidelines for NAFLD/ NASH
Table 4.2 Plant Extracts Used for the Treatment of NASH
Table 4.3 Polyherbal Medications for Management of NASH
Table 4.4 Phytochemicals for Treatment of NASH
Table 4.5 NASH: Non-invasive Imaging Diagnostic Methods
Table 6.1 NASH: Pipeline of Drugs
Table 7.1 NASH: Molecules in Late Stage of Development
Table 7.2 Saroglitazar: Clinical Trials
Table 7.3 Saroglitazar: Patent Portfolio
Table 7.4 FLINT Trial: Key Baseline Charcateristics
Table 7.5 INT-747: Research and Development Expenses
Table 7.6 INT-747: Patent Portfolio
Table 7.7 Emricasan: Phase 1 Clinical Trial Summary
Table 7.8 Emricasan: Clinical Trial Results
Table 7.9 GFT505: Clinical Trials
Table 7.10 CVC: Clinical Trials
Table 7.11 CVC: Patent Portfolio
Table 7.12 Aramchol: Clinical Trials
Table 7.13 Aramchol: Important Paramters of ARREST Study
Table 7.14 Aramchol: Completed Clinical Trials
Table 7.15 Simtuzumab: Clinical Trials
Table 7.16 Simtuzumab: Patent Portfolio
Table 7.17 RP103: Clinical Trials
Table 7.18 RP103: Treatment Regimen
Table 7.19 RP103: Patent Portfolio
Table 7.20 Remogliflozin etabonate: Clinical Development Overview
Table 7.21 Remogliflozin etabonate: Patent Portfolio
Table 8.1 Opportunity Analysis: Target Patient Population
Table 8.2 Opportunity Analysis: Diagnosis Rate
Table 8.3 Opportunity Analysis: Drug Penetration Rates
Table 8.4 Opportunity Analysis: Price of the Drug
Table 9.1 INT-747: Planned 2015 Milestones
Table 12.1 Rise in Overweight and Obesity Rate, 1980-2013
Table 12.2 Diabetes: Worldwide Prevalence and Diagnosis (Million)
Table 12.3 Diabetes: Prevalence by Regions/ Countries (2014), Million
Table 12.4 Diabetes: Diagnosed Cases by Regions/ Countries (2014), Million
Table 12.5 NASH Drugs: Distribution by Phase of Development
Table 12.6 NASH Drugs: Distribution by Type of Molecule
Table 12.7 NASH Drugs: Distribution by Route of Administration
Table 12.8 Overall NASH Drugs Market, 2018-2025 (USD Million)
Table 12.9 NASH Drugs Market: Indicative Distribution by Drugs: 2020, 2025
Table 12.10 Market Scenarios, Comparative Positioning (USD Billion)
Table 12.11 Genfit: Revenues, 2010-2014 (EUR Million)
Table 12.12 Genfit: Distribution of Revenues, 2014 (EUR Billion)
Table 12.13 Gilead Sciences: Net Revenues, 2010 – H1 2015 (USD Billion)
Table 12.14 Gilead Sciences: Distribution of Revenues, 2014 (USD Million)
Table 12.15 Intercept Pharmaceuticals: Revenues, 2011- H1 2015 (USD Million)
Table 12.16 Novo Nordisk Revenues, 2010 – H1 2015 (DKK Million)
Table 12.17 Novo Nordisk Revenues: Distribution by Business Segment, 2014 (DKK Billion)
Table 12.18 Raptor Pharmaceuticals: Revenues, 2013-H1 2015 (USD Million)
Table 12.19 Zydus Cadila: Revenues, 2010-2014 (INR Billion)
Table 12.20 Zydus Cadila: Revenues by Geographies, 2014 (INR Billion)
Table 12.21 Nash Drugs Market (USD Million), 2018, 2020, and 2015
The following companies and organizations have been mentioned in this report